LONDON (Alliance News) - Vectura Group PLC Wednesday confirmed data from Novartis AG regarding positive results from a Phase III study comparing its Utilbro Breezhaler with GlaxoSmithKline PLC's Seretide Accuhaler for the treatment of chronic obstructive pulmonary disease. In the test Ultib Read More

Vectura Triggers Final Milestone Payment Under 2010 Glaxo Licensing Deal

29th Apr 2014 11:16

LONDON (Alliance News) - Respiratory treatment development company Vectura Group PLC Tuesday said it has triggered a GBP2 million milestone payment from GlaxoSmithKline PLC, a day after the drugs giant launched its chronic obstructive pulmonary disease treatment Anoro Ellipta in the US. Gla Read More

Vectura To Begin European Study For Asthma Treatment Favolir In 2014

11th Apr 2014 07:59

LONDON (Alliance News) - Vectura Group PLC said Friday that it will begin a "pivotal" study in Europe later in 2014 for its product Favolir in the treatment of severe, uncontrolled asthma. The company said that the study is part of its strategy for a broad development programme across Europ Read More

Vectura Triggers USD3 Million Milestone Payment For VR315 Development

25th Mar 2014 13:40

LONDON (Alliance News) - Vectura Group PLC said Tuesday that it had triggered a USD3 million development milestone payment through the development of its VR315 product in the US with a pharmaceutical company. Vectura did not name the pharmaceutical company. Vecture is eligible to rece Read More

UK BROKER RATINGS: Morgan Stanley Raises SSE To Overweight

20th Mar 2014 10:16

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning: ---------- FTSE 100 ---------- UBS CUTS SMITHS GROUP PRICE TARGET TO 1220 (1340) PENCE - 'SELL' ---------- JPMORGAN CUTS SMITHS GROUP PRICE TARGET Read More

Vectura Says AirFluSal Forspiro Has First Asian Approval, From South Korea

28th Feb 2014 10:51

LONDON (Alliance News) - Inhaler company Vectura Group PLC Friday said its partner Sandoz has received marketing approval for its AirFluSal Forspiro inhaler for treating asthma and chronic obstructive pulmonary disease, the first approval for the product in Asia. Vectura developed the produ Read More

Vectura Says Performing In Line With Expectations

13th Feb 2014 12:00

LONDON (Alliance News) - Vectura Group PLC said Thursday that its performance in the period from October 1, 2013 to date had been in line with expectations. During the period Vectura's partner Sandoz saw marketing authorisation for AirFluSal Forspiro, an inhaler for asthma or Chronic Obstru Read More

UK MORNING BRIEFING: Lloyds To Set Out New Strategy By End Of 2014

13th Feb 2014 08:24

LONDON (Alliance News) - The market is dissecting the Lloyds Banking Group earnings statement early Thursday. The state-controlled bank said it swung to profit in 2013, while confirming its intentions to restart paying a dividend and to sell off more of the UK government's sha Read More

Vectura To Receive EUR1.5 Million After Inhaler Wins Belgian Approval

12th Feb 2014 15:29

LONDON (Alliance News) - Vectura Group PLC Wednesday said its partner has received Belgian marketing authorisation for its new inhaler for people with asthma, triggering a payment to Vectura of EUR1.5 million. In a statement, Vectura said partner Sandoz has received approval for the AirFluS Read More

Vectura Partner Gets Norwegian Marketing Authorisation For Asthma Inhaler

10th Feb 2014 16:47

LONDON (Alliance News) - LONDON (Alliance News) - Vectura Group PLC Monday said partner Sandoz has received marketing authorisation from Norwegian authorities for its asthma inhaler AirFluSal Forspiro. It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary, R Read More

FTSE 100 Latest

Value8,809.74

Change53.53